FilingsTodaySamjin Pharmaceutical
At a glance
Samjin Pharmaceutical filed 49 disclosures in the last 12 months, including 15 insider, 9 5% holder and 2 buyback. The most recent key filing was on Sep 2.
Revenue for 2025 was ₩309B, up 0.3% on 2024. Operating margin was 8.7% against 10.3% a year earlier. Debt was 62% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩148B and operating profit of ₩10.7B.
The 2025 annual report lists 819 employees with an average tenure of 12.2 years and average pay of ₩81.5M, #346 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩963.9M each on average. It paid ₩800 per common share in cash dividends, against ₩800 a year earlier (+0%). 조의환 and related parties held 13.41% at year end.
From the 2025 annual report
Staff: 819 (568 men, 251 women), of whom 29 on fixed-term contracts. Total pay for the year: ₩67B. Directors and auditors: 8, paid ₩7.7B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩800 | ₩800 | ₩800 |
| Payout ratio | 41.9% | 25% | 54.1% |
| Yield (as filed) | 3.87% | 4.31% | 3.66% |
| Total cash dividends | ₩10.1B | ₩9.8B | ₩10.2B |
Largest shareholder
조의환 holds 6.30%; with 3 related parties the group holds 13.41% of common shares at year end (from 12.85% at the start of the year).
Individuals paid ₩500M or more
| 최용주 대표이사 사장 | ₩5.2B |
| 조규석 대표이사 사장 | ₩663.5M |
| 최지현 대표이사 사장 | ₩663.5M |
| 조규형 부사장 | ₩524M |
| 최지선 부사장 | ₩524M |
Auditor: 한울회계법인 · opinion: Unqualified.
Rankings: Director pay #49 of 2,157
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.